Table 1.
General features and cognitive scores of subjects.
| Aβ−NC (n = 12) | Aβ+MCI (n = 32) | Aβ+AD (n = 16) | p value | |
|---|---|---|---|---|
| Age, years | 71 (66, 78) | 73 (69, 79) | 71 (63, 77) | 0.353 |
| Female, % | 83.33% | 59.40% | 68.80% | 0.102 |
| DM, % | 25.00% | 15.60% | 6.30% | 0.384 |
| HTN, % | 50.00% | 46.90% | 56.30% | 0.829 |
| Smoking, % | 8.00% | 15.60% | 12.60% | 0.399 |
| Alcohol, % | 8.00% | 25.00% | 18.80% | 0.249 |
| Right-handed, % | 100.00% | 90.60% | 93.30% | 0.235 |
| Education, years | 12.0 (7.5, 14.0) | 12.0 (9.8, 16.0) | 7.5 (6.0, 9.8) | 0.006* |
| APOE4 carrier† | 0.00% | 57.70% | 70.00% | <0.001* |
| MMSE score | 29.0 (27.0, 30.0) | 26.0 (24.3, 28.0) | 18.0 (11.3, 22.8) | <0.001* |
| CDR score | 0.0 (0.0, 0.0) | 0.5 (0.5, 0.5) | 1.0 (0.6, 1.8) | <0.001* |
| CDR-SB score | 0.0 (0.0, 0.0) | 1.5 (0.5, 2.4) | 6.0 (4.1, 9.8) | <0.001* |
Values are reported as medians with interquartile ranges. P-values were calculated using the Kruskal-Wallis test. *P-values are significant at the 0.05 level. †APOE4 genotyping was available in 12 subjects in the Aβ−NC group, 26 subjects in the Aβ+MCI group, and 10 subjects in the Aβ+AD group. Abbreviations: Aβ−NC, Aβ-negative normal cognition; Aβ+MCI, Aβ-positive mild cognitive impairment; Aβ+AD, Aβ-positive Alzheimer’s disease with dementia; DM, diabetes mellitus; HTN, hypertension; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating; CDR-SB, Clinical Dementia Rating Scale Sum of Boxes.